In drug discovery, the key to success often depends on the models used. This webinar discusses how Charles River’s model creation partner, Mirimus, has leveraged RNA interference (RNAi) and CRISPR/Cas9 technologies to enhance the speed and precision of new genetically engineered mouse models. This robust system provides a cost-effective, scalable platform for the production of mice with enormous predictive power that will shape development of better-tolerated therapies, pushing drug discovery research into a new era.


  • Prem K. Premsrirut, MD, PhD, President/CEO
    Mirimus, Inc.